serena williams glp 1 ad Serena's on Ro Serena Williams is in a

Levine and her team will review your medical background, assess your metabolic profile, and explain what you can realistically expect from microdosing

Mounjaro (Tirzepatide) The Game Changer Now officially licensed in Thailand Dual-action: GLP-1 and GIP receptor agonist Delivers superior appetite regulation and improved insulin sensitivity Clinical trials show up to 22.5% total body weight reduction (one of the highest across all medications) Weekly injection with flexible dosing (2.5mg15mg) Approved for Type 2 diabetes, but increasingly prescribed off-label for weight loss worldwide Unique advantage: targets two hormones , making it a potential first-choice option for patients who havent succeeded with other injectables 4

EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms The 2023 nonhormone therapy position statement of The North American Menopause Society References Hickey M et al

According to District Collector Carmelita M